SCHEMBL10185276

SCHEMBL10185276

CCOC(=O)c1cnn2cc(-c3cccnc3)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 1/20 0.56
RAB9A P51151 5/20 0.53
NPC1 O15118 4/20 0.53
MMP2 P08253 1/20 0.48
MMP13 P45452 1/20 0.48
MMP14 P50281 1/20 0.48
NR4A2 P43354 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MKNK1 Q9BUB5 2/20 0.44
MKNK2 Q9HBH9 2/20 0.44
CDC7 O00311 1/20 0.43
DBF4 Q9UBU7 1/20 0.43
TP53 P04637 2/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
PIK3CA P42336 1/20 0.42
PIK3CG P48736 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HPGD P15428 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294889 0.82 ALDH1A1 (0.53) RAB9ANPC1ALDH1A1TSHRNPSR1
SCHEMBL10185277 0.81 MKNK1 (0.51) NR4A2ALDH1A1MKNK1MKNK2CYP11B1
SCHEMBL31212715 0.81 USP30 (0.49) RAB9ANPC1ALDH1A1PIK3CGHPGD
SCHEMBL14743171 0.79 JAK3 (0.44) RAB9ANPC1ALDH1A1TP53TSHR
SCHEMBL1290693 0.79 ALDH1A1 (0.52) RAB9ANPC1ALDH1A1TP53TSHR
SCHEMBL15897858 0.77 CA12 (0.48) RAB9ANPC1ALDH1A1TP53TSHR
SCHEMBL24369875 0.76 EPHB3 (0.50) RAB9ANPC1ALDH1A1TSHRHPGD
SCHEMBL2288847 0.76 LMNA (0.49) RAB9ANPC1ALDH1A1TSHRHPGD
SCHEMBL1290663 0.76 ALDH1A1 (0.48) RAB9ANPC1ALDH1A1TSHRHPGD
SCHEMBL15368028 0.76 ALDH1A1 (0.44) RAB9ANPC1ALDH1A1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF DCTPP1 1832/4885RAB9A 614/4885NPC1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.